Monte Rosa Q2 net loss $18.4M; $255.6M IPO extends cash into late 2024

Monte Rosa Therapeutics, Inc.

R&D expenses $14.6M (Q2 2020: $4.9M), G&A $3.5M ($0.5M) as headcount and lab activities expanded.
Cash and equivalents $357.1M at June 30, 2021; plus $31M net from IPO underwriters' option exercise.
NEK7 NLRP3 degrader program advanced into lead optimization; GSPT1 candidate selection anticipated before year-end.
Appointed Filip Janku, M.D., Ph.D. as CMO; opened research centers in Boston Seaport and Basel.
Anticipates at least one additional program entering lead optimization by end of 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.